Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-27

Incyte Corp (INCY)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$32,085,952
William Meury total, FY2025
91st
CEO pay percentile vs peers
110.47:1
CEO-to-median pay ratio
83.86%
Say-on-pay support, latest vote
Companies that benchmark against INCY
27 companies name INCY as a compensation peer

Each company listed discloses INCY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INCY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
William Meury$647,260$0$27,509,657$2,573,998$1,300,000$0$55,037$32,085,952
Chief Executive Officer
Mohamed Issa690,4111,000,0007,870,118450,983533,610047,66010,592,782
Executive Vice President and Head of U.S. Commercial
Pablo Cagnoni966,51604,952,3781,815,1591,007,027097,8818,838,961
President and Global Head of Research and Development
Herve Hoppenot1,392,49901,971,9751,694,0341,026,0720295,9456,380,525
Former President and Chief Executive Officer
Steven Stein835,06703,466,6751,270,592696,054035,7846,304,172
Executive Vice President, Chief Medical Officer and Head of Late-stage Development
Christiana Stamoulis520,83903,136,4681,149,58800129,6554,936,550
Former Executive Vice President and Chief Financial Officer
Thomas Tray358,1890305,897154,623149,423022,236990,368
Vice President, Chief Accounting Officer and Principal Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
William Meury$32,085,952
Mohamed Issa10,592,782
Pablo Cagnoni8,838,961
Herve Hoppenot6,380,52517,459,54616,659,526−11,079,021
Steven Stein6,304,1725,979,828+324,344
Christiana Stamoulis4,936,550
Thomas Tray990,368

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A26,343$0$0CommonForm 4 ↗
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A13,17100Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A38,42900Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-05-06A31,51700CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-05-06A44,12400CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08D15,00000Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08A15,000851,267,950CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08D15,00000Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08A15,000851,267,950CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19A15,000851,267,950CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19D15,00000Derivative, Class A CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19D15,000951,423,950CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-05-26D2,05197199,665CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26D13,059971,268,029CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26A15,000851,267,950CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26D15,00000Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-06-01D25,469962,434,582CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04D2,63900Derivative, Class A CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04D2,639100263,900CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04A2,63984221,227CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Paul J. ClancyDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A1,64200CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-08A1,64200CommonForm 4 ↗
Paul J. ClancyDirector2026-06-08A1,64200CommonForm 4 ↗
Jacqualyn A. FouseDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-08A1,64200CommonForm 4 ↗
Katherine A. HighDirector2026-06-08A1,64200CommonForm 4 ↗
Katherine A. HighDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Otis W. BrawleyDirector2026-06-08A1,64200CommonForm 4 ↗
Otis W. BrawleyDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Jacqualyn A. FouseDirector2026-06-08A1,64200CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A1,64200CommonForm 4 ↗
Paul J. ClancyDirector2026-06-30A25211328,567CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-30A40000CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-30A40000CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-30A25511328,907CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-02D47711755,742CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-02D35011740,901CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-02D2,177117254,404CommonForm 4 ↗
William MeuryDirector2026-07-02D4,779117558,474CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-14D1,512115174,016CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-14D1,098115126,369CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-14D69211579,497CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-14D17,9691152,064,279CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-14D43711550,203CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-14D28,2371133,192,193CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-14D4,950115569,696CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-14D21,8301152,507,830CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-14D3,088115355,398CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-15D1,099115126,484CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A7,85700CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A42,29800Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A57,86100Derivative, Class A CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A31,92300Derivative, Class A CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16D1,877115215,348CommonForm 4 ↗
William MeuryDirector2026-07-16A80,42100Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A13,40300CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16D1,093115125,706CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A21,54800Derivative, Class A CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A31,92300Derivative, Class A CommonForm 4 ↗
William MeuryDirector2026-07-16A26,80700CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A5,91600CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-16A2,83400CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A25,53800Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A19,64300Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A33,50800Derivative, Class A CommonForm 4 ↗
William MeuryDirector2026-07-16A77,14800Derivative, Class A CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A18,48700Derivative, Class A CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A7,39500CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A18,48700Derivative, Class A CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A7,39500CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A12,47900Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A33,91800Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A14,79000Derivative, Class A CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-16A4,07900Derivative, Class A CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A9,79800CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A24,49600Derivative, Class A CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A4,99100CommonForm 4 ↗
Lee HeesonEVP, Head of Incyte Intl2026-07-23A15,42300Derivative, Class A CommonForm 4 ↗
Michael James MorrisseyEVP, Head of Tech. Operations2026-07-23A6,42600Derivative, Class A CommonForm 4 ↗
Michael James MorrisseyEVP, Head of Tech. Operations2026-07-23A8,99900Derivative, Class A CommonForm 4 ↗
Lee HeesonEVP, Head of Incyte Intl2026-07-23A13,49800Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mohamed IssaPSU2025-07-158,76913$598,484
Mohamed IssaRSU2025-01-0648,6713,499,932
Pablo CagnoniOPTION2025-07-1539,471901,981
Christiana StamoulisPSU2025-07-1511,10713758,053
Pablo CagnoniOPTION2025-01-1740,289913,178
William MeuryPSU2025-07-0254,152108,303216,6069,276,152
Steven SteinPSU2025-07-151230,69261,3842,628,770
Christiana StamoulisPSU2025-07-151227,76955,5382,378,415
Thomas TrayOPTION2025-07-153,36276,833
Christiana StamoulisOPTION2025-01-1725,516578,338
Mohamed IssaPSU2025-07-151221,92343,8461,877,705
Mohamed IssaPSU2025-06-3027,812141,893,997
Thomas TrayPSU2025-07-154,48213305,897
Steven SteinPSU2025-07-1512,27713837,905
Mohamed IssaOPTION2025-07-1519,735450,983
Herve HoppenotOPTION2025-06-2611428,997
Thomas TrayOPTION2025-01-173,43277,790
Steven SteinOPTION2025-01-1728,202639,221
William MeuryPSU2025-07-02125,000500,00015,772,500
Steven SteinOPTION2025-07-1527,629631,371
Herve HoppenotOPTION2016-01-07156,866
Herve HoppenotPSU2025-06-266,01613425,993
Christiana StamoulisOPTION2025-07-1524,998571,250
Herve HoppenotOPTION2025-01-17101,258,171
Pablo CagnoniPSU2025-07-1517,538131,196,969
William MeuryRSU2025-07-0236,1012,461,005
William MeuryOPTION2025-06-26110,6302,573,998
Pablo CagnoniPSU2025-07-151243,84687,6923,755,409
Herve HoppenotPSU2025-06-261218,05036,1001,545,982
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mohamed Issa$3,499,932$4,370,186$450,98352.5%
Pablo Cagnoni04,952,3781,815,15973.2%
Christiana Stamoulis03,136,4681,149,58873.2%
William Meury2,461,00525,048,6522,573,99883.3%
Steven Stein03,466,6751,270,59273.2%
Thomas Tray0305,897154,62366.4%
Herve Hoppenot01,971,9751,694,03453.8%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
William MeuryRSU125,000$12,346,250
William MeuryRSU36,1013,565,696
Herve HoppenotOption11,94277.67
Steven SteinRSU34,7393,431,171
Pablo CagnoniOption28,68364.25
Mohamed IssaRSU21,9232,165,335
Pablo CagnoniRSU117,64311,619,599
Steven SteinRSU6,768668,475
Pablo CagnoniRSU17,5381,732,228
Mohamed IssaRSU8,769866,114
Mohamed IssaOption19,73568.25
Thomas TrayRSU3,805375,820
William MeuryRSU108,30310,697,087
Pablo CagnoniPSU229,66122,683,617
Pablo CagnoniOption8,64761.18
Mohamed IssaRSU48,6714,807,235
Thomas TrayOption1,79461.18
Pablo CagnoniOption26,02171.93
Steven SteinPSU34,2033,378,230
Pablo CagnoniOption39,47168.25
Pablo CagnoniRSU49,6274,901,659
Pablo CagnoniRSU14,8891,470,587
Thomas TrayRSU2,833279,815
Thomas TrayOption2,44464.25
Steven SteinOption11,23661.76
Steven SteinOption3,95283.2
Thomas TrayRSU4,482442,687
Pablo CagnoniOption8,02661.76
Thomas TrayRSU1,038102,523
Steven SteinOption3,74377.67
Pablo CagnoniRSU43,8464,330,669
Thomas TrayOption41077.67
Herve HoppenotOption35,85171.93
Thomas TrayOption2,21771.93
Thomas TrayOption43383.2
Herve HoppenotOption12,60883.2
Herve HoppenotRSU123,07612,156,217
Thomas TrayOption1,66561.76
Herve HoppenotRSU107,96010,663,209
Herve HoppenotPSU70,6436,977,409
Herve HoppenotRSU29,4682,910,554
Herve HoppenotRSU20,6842,042,959
Herve HoppenotRSU18,0501,782,799
Herve HoppenotOption38,62161.18
Herve HoppenotRSU14,4751,429,696
Herve HoppenotOption35,84961.76
Herve HoppenotRSU6,016594,200
Herve HoppenotOption18,43870.81
Steven SteinRSU12,2771,212,599
Steven SteinRSU10,4221,029,381
Steven SteinOption27,62968.25
Herve HoppenotOption39,51964.25
Pablo CagnoniRSU4,834477,454
Steven SteinRSU4,736467,775
Herve HoppenotRSU249,08624,602,225
Steven SteinOption12,10561.18
Pablo CagnoniRSU192,40019,003,348
Thomas TrayRSU3,008297,100
Pablo CagnoniRSU24,1702,387,271
Steven SteinRSU99,2699,804,799
Steven SteinRSU33,8383,342,179
Steven SteinOption20,07864.25
Mohamed IssaRSU27,8122,746,991
Steven SteinRSU30,6923,031,449
Thomas TrayOption2,45468.25
Steven SteinOption18,21571.93
William MeuryOption110,63070.81
05

Incentive-plan design — the Compensation Discussion & Analysis

We align executive pay with performance, ensuring that a significant portion of total compensation is tied to the achievement of both near-term priorities and long-term strategic goals. This includes advancing our pipeline, strengthening our commercial capabilities, and delivering sustained shareholder value.

CEO STI target (% of salary)110%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-08145,851,78428,078,013290,89183.86%Passed
20252025-04-11153,838,97213,020,842571,30192.2%Passed
20242024-06-12171,688,04019,939,207336,17289.59%Passed
20232023-06-14169,320,95223,663,412241,86087.74%Passed
20222022-06-15170,569,04917,789,07582,01290.56%Passed
20212021-05-13175,778,84114,039,03889,35692.6%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0883.86%a
20252025-04-1192.2%b
20242024-06-1289.59%c

a. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.

b. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.

c. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)110.47 : 1
CEO total compensation$32,688,692
Median employee compensation$295,914
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Julian C. BakerIndependent · Board Chair · Nominating and Corporate Governance (Chair) · Compensation$308,436$264,702$0$0$573,138
Edmund P. HarriganIndependent · Science and Technology (Chair) · Audit and Finance274,936264,70200539,638
Paul J. ClancyIndependent · Audit and Finance (Chair) · Compensation273,436264,70200538,138
Jean-Jacques BienaimIndependent · Compensation (Chair) · Nominating and Corporate Governance95,000176,436264,70200536,138
Jacqualyn A. FouseIndependent · Audit and Finance · Nominating and Corporate Governance83,500176,436264,70200524,638
Susanne SchaffertIndependent · Compensation · Science and Technology · Not standing for re-election · Departed during FY82,000176,436264,70200523,138
Otis W. BrawleyIndependent · Science and Technology70,000176,436264,70200511,138
Katherine A. HighIndependent · Science and Technology70,000176,436264,70200511,138
Herve HoppenotEmployee director · Not standing for re-election · Departed during FY00000
William J. MeuryEmployee director · Newly elected00000
09

Board fee structure and ownership guideline

Annual cash retainer$65,000
Annual equity retainer$400,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)25,000 / 25,000 / 20,000
Stock ownership guideline6x Annual Cash Retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$400,500
Equity awards (grant-date value)$1,738,988
All other compensation$0
Total cost of the board$2,139,488

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Incyte Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Incyte Corp.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis, Inc.2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2Incyte Corp2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
3Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
4PTC Therapeutics, Inc.2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
5BioMarin Pharmaceutical Inc.2025Alexander Hardy1,130,76916,833,6291,909,3101,644,50021,927,563
6Moderna, Inc.2025Stéphane Bancel1,677,7396,897,4556,897,4254,302,36019,932,217
7Jazz Pharmaceuticals plc2025Renee Gala1,003,26916,138,43301,980,00019,151,558
8United Therapeutics Corporation2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
9BeOne Medicines Ltd.2025John Oyler1,133,00011,249,6153,749,9671,676,84017,943,521
10Natera, Inc.2025Steven Chapman853,71012,979,55801,114,15114,957,319
11Alnylam Pharmaceuticals, Inc.2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
12Neurocrine Biosciences, Inc.2025Kyle Gano920,0005,750,0235,750,006013,448,935
13Illumina, Inc.2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
argenx SEnot in coverage universe
Genmab A/Snot in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Incyte Corp138.6%PSU 60 · Options 20 · RSU 20Yes — relative total shareholder return (TSR)Aon
Alnylam Pharmaceuticals, Inc.200%PSU 50 · RSU 25 · Options 25NoPay Governance
argenx SEnot disclosednot disclosednot disclosednot disclosed
BeOne Medicines Ltd.148%PSU 50 · Options 25 · RSU 25NoPay Governance
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
BioMarin Pharmaceutical Inc.130%PSU 66 · RSU 21 · Options 13Yes — Relative TSRAon Human Capital Solutions
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Genmab A/Snot disclosednot disclosednot disclosednot disclosed
Illumina, Inc.1155%not disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon (Aon's Human Capital Practice, a division of Aon, plc)
Jazz Pharmaceuticals plc150%PSU 50 · RSU 50Yes — Relative TSRAon
Moderna, Inc.170%PSU 50 · Options 50NoPay Governance LLC
Natera, Inc.131.1%PSU 50 · RSU 50NoAon
Neurocrine Biosciences, Inc.105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
PTC Therapeutics, Inc.167%Options 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFW Cook
United Therapeutics Corporation221%Options 50 · PSU 50NoAon Human Capital Solutions

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Incyte Corp in fiscal 2025?
The highest-paid executive at Incyte Corp in fiscal 2025 was William Meury, Chief Executive Officer, with total compensation of $32,085,952.
How does Incyte Corp's chief executive pay compare to its disclosed peer group?
The CEO's pay was at the 91st percentile of disclosed peers.
What is Incyte Corp's CEO-to-median employee pay ratio?
The CEO-to-median employee pay ratio was 110.47:1.
How did shareholders vote on Incyte Corp's executive compensation?
Shareholders voted 83.86% in support of the executive compensation plan.
How much does Incyte Corp spend in total on board compensation for fiscal 2025?
Total board compensation for fiscal 2025 was $2,139,488.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, William MeuryDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
2Section 01, Mohamed IssaDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 10,592,782. Filing ↗machine: span 660264–660274
3Section 01, Pablo CagnoniDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 8,838,961. Filing ↗machine: r6 · c30 · span 650737–650746
4Section 01, Herve HoppenotDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 6,380,525. Filing ↗machine: t91 · r3 · c16 · span 641487–641496
5Section 01, Steven SteinDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 6,304,172. Filing ↗machine: r10 · c30 · span 663627–663636
6Section 01, Christiana StamoulisDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 4,936,550. Filing ↗machine: r13 · c30 · span 672876–672885
7Section 01, Thomas TrayDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 990,368. Filing ↗machine: r16 · c30 · span 682687–682694
8Section 03, Mohamed Issa PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r24 · c21 · span 794174–794181
9Section 03, Mohamed Issa RSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r20 · c21 · span 784652–784661
10Section 03, Pablo Cagnoni OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r16 · c21 · span 775094–775101
11Section 03, Christiana Stamoulis PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r34 · c21 · span 818355–818362
12Section 03, Pablo Cagnoni OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r15 · c21 · span 772731–772738
13Section 03, William Meury PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r6 · c23 · span 751118–751127
14Section 03, Steven Stein PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r28 · c23 · span 804062–804071
15Section 03, Christiana Stamoulis PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r33 · c23 · span 816155–816164
16Section 03, Thomas Tray OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r37 · c21 · span 825512–825518
17Section 03, Christiana Stamoulis OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r31 · c21 · span 811034–811041
18Section 03, Mohamed Issa PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r23 · c23 · span 791975–791984
19Section 03, Mohamed Issa PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r21 · c21 · span 786852–786861
20Section 03, Thomas Tray PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r38 · c12 · span 827154–827159
21Section 03, Steven Stein PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r29 · c21 · span 806262–806269
22Section 03, Mohamed Issa OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r22 · c15 · span 788325–788331
23Section 03, Herve Hoppenot OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r10 · c21 · span 760644–760651
24Section 03, Thomas Tray OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r36 · c21 · span 823151–823157
25Section 03, Steven Stein OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r26 · c21 · span 798941–798948
26Section 03, William Meury PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r5 · c23 · span 748356–748366
27Section 03, Steven Stein OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r27 · c21 · span 801304–801311
28Section 03, Herve Hoppenot OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r11 · c21 · span 763007–763012
29Section 03, Herve Hoppenot PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r13 · c21 · span 767961–767968
30Section 03, Christiana Stamoulis OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r32 · c21 · span 813397–813404
31Section 03, Herve Hoppenot OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r9 · c21 · span 758279–758288
32Section 03, Pablo Cagnoni PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r18 · c21 · span 780052–780061
33Section 03, William Meury RSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r7 · c21 · span 753317–753326
34Section 03, William Meury OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r4 · c15 · span 744702–744709
35Section 03, Pablo Cagnoni PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r17 · c23 · span 777852–777861
36Section 03, Herve Hoppenot PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r12 · c23 · span 765762–765771
37Section 07, pay ratioDEF 14A2026-04-280000879169-26-000031Section “CEO Pay Ratio”. As printed: 110.47 : 1. Filing ↗machine: span 1232682–1232693
38Section 08, Julian C. BakerDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 573,138. Filing ↗machine: t50 · r2 · c7 · span 307929–307936
39Section 08, Edmund P. HarriganDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 539,638. Filing ↗machine: t50 · r7 · c7 · span 316313–316320
40Section 08, Paul J. ClancyDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 538,138. Filing ↗machine: t50 · r5 · c7 · span 312960–312967
41Section 08, Jean-Jacques BienaimDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 536,138. Filing ↗
42Section 08, Jacqualyn A. FouseDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 524,638. Filing ↗machine: t50 · r6 · c7 · span 314636–314643
43Section 08, Susanne SchaffertDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 523,138. Filing ↗machine: t50 · r9 · c7 · span 320130–320137
44Section 08, Otis W. BrawleyDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 511,138. Filing ↗machine: t50 · r4 · c7 · span 311287–311294
45Section 08, Katherine A. HighDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 511,138. Filing ↗machine: t50 · r8 · c7 · span 317988–317995
46Section 08, Herve HoppenotDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 0. Filing ↗
47Section 08, William J. MeuryDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 0. Filing ↗
48Section 02, Suketu Upadhyay 2026-05-04Form 42026-05-060001533149-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Suketu Upadhyay 2026-05-04Form 42026-05-060001533149-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Suketu Upadhyay 2026-05-04Form 42026-05-060001533149-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Pablo Cagnoni 2026-05-06Form 42026-05-200001205703-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Steven Stein 2026-05-06Form 42026-05-200001673776-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, BAKER BROS. ADVISORS LP 2026-05-08Form 42026-05-110001193125-26-216988Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, BAKER BROS. ADVISORS LP 2026-05-08Form 42026-05-110001193125-26-216988Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, BAKER BROS. ADVISORS LP 2026-05-08Form 42026-05-110001193125-26-216988Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, BAKER BROS. ADVISORS LP 2026-05-08Form 42026-05-110001193125-26-216988Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Paul J. Clancy 2026-05-19Form 42026-05-210001409601-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Paul J. Clancy 2026-05-19Form 42026-05-210001409601-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Paul J. Clancy 2026-05-19Form 42026-05-210001409601-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Thomas Tray 2026-05-26Form 42026-05-280001912317-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Jean Jacques Bienaime 2026-05-26Form 42026-05-280001221590-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Jean Jacques Bienaime 2026-05-26Form 42026-05-280001221590-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Jean Jacques Bienaime 2026-05-26Form 42026-05-280001221590-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Pablo Cagnoni 2026-06-01Form 42026-06-030001205703-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Thomas Tray 2026-06-04Form 42026-06-080001912317-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Thomas Tray 2026-06-04Form 42026-06-080001912317-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Thomas Tray 2026-06-04Form 42026-06-080001912317-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Edmund P. Harrigan 2026-06-08Form 42026-06-100001177917-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Paul J. Clancy 2026-06-08Form 42026-06-100001409601-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, BAKER BROS. ADVISORS LP 2026-06-08Form 42026-06-100001193125-26-265952Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, BAKER BROS. ADVISORS LP 2026-06-08Form 42026-06-100001193125-26-265952Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Edmund P. Harrigan 2026-06-08Form 42026-06-100001177917-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Paul J. Clancy 2026-06-08Form 42026-06-100001409601-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Jacqualyn A. Fouse 2026-06-08Form 42026-06-100001405288-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Jean Jacques Bienaime 2026-06-08Form 42026-06-100001221590-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Katherine A. High 2026-06-08Form 42026-06-100001631248-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Katherine A. High 2026-06-08Form 42026-06-100001631248-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Otis W. Brawley 2026-06-08Form 42026-06-100001213029-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Otis W. Brawley 2026-06-08Form 42026-06-100001213029-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, BAKER BROS. ADVISORS LP 2026-06-08Form 42026-06-100001193125-26-265952Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Jacqualyn A. Fouse 2026-06-08Form 42026-06-100001405288-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Jean Jacques Bienaime 2026-06-08Form 42026-06-100001221590-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, BAKER BROS. ADVISORS LP 2026-06-08Form 42026-06-100001193125-26-265952Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Paul J. Clancy 2026-06-30Form 42026-07-020001409601-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, BAKER BROS. ADVISORS LP 2026-06-30Form 42026-07-020001193125-26-294712Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, BAKER BROS. ADVISORS LP 2026-06-30Form 42026-07-020001193125-26-294712Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Edmund P. Harrigan 2026-06-30Form 42026-07-020001177917-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Thomas Tray 2026-07-02Form 42026-07-070001912317-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Patrick A. Mayes 2026-07-02Form 42026-07-070002079962-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Steven Stein 2026-07-02Form 42026-07-070001673776-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, William Meury 2026-07-02Form 42026-07-070001536778-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Patrick A. Mayes 2026-07-14Form 42026-07-160002079962-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Thomas Tray 2026-07-14Form 42026-07-160001912317-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Thomas Tray 2026-07-14Form 42026-07-160001912317-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Pablo Cagnoni 2026-07-14Form 42026-07-160001205703-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Patrick A. Mayes 2026-07-14Form 42026-07-160002079962-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Steven Stein 2026-07-14Form 42026-07-160001673776-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Pablo Cagnoni 2026-07-14Form 42026-07-160001205703-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Steven Stein 2026-07-14Form 42026-07-160001673776-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Steven Stein 2026-07-14Form 42026-07-160001673776-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Mohamed Issa 2026-07-15Form 42026-07-160002050035-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Mohamed Issa 2026-07-16Form 42026-07-200002050035-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Steven Stein 2026-07-16Form 42026-07-200001673776-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Pablo Cagnoni 2026-07-16Form 42026-07-200001205703-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Richard A. Hoffman 2026-07-16Form 42026-07-200002098091-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Steven Stein 2026-07-16Form 42026-07-200001673776-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, William Meury 2026-07-16Form 42026-07-200001536778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Pablo Cagnoni 2026-07-16Form 42026-07-200001205703-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Mohamed Issa 2026-07-16Form 42026-07-200002050035-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Ramitpal K. Basi 2026-07-16Form 42026-07-200002083591-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, David H. Gardner 2026-07-16Form 42026-07-200002085970-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, William Meury 2026-07-16Form 42026-07-200001536778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Patrick A. Mayes 2026-07-16Form 42026-07-200002079962-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Thomas Tray 2026-07-16Form 42026-07-200001912317-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Patrick A. Mayes 2026-07-16Form 42026-07-200002079962-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Mohamed Issa 2026-07-16Form 42026-07-200002050035-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Pablo Cagnoni 2026-07-16Form 42026-07-200001205703-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, William Meury 2026-07-16Form 42026-07-200001536778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Richard A. Hoffman 2026-07-16Form 42026-07-200002098091-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Richard A. Hoffman 2026-07-16Form 42026-07-200002098091-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, David H. Gardner 2026-07-16Form 42026-07-200002085970-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, David H. Gardner 2026-07-16Form 42026-07-200002085970-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Ramitpal K. Basi 2026-07-16Form 42026-07-200002083591-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Mohamed Issa 2026-07-16Form 42026-07-200002050035-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Patrick A. Mayes 2026-07-16Form 42026-07-200002079962-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Thomas Tray 2026-07-16Form 42026-07-200001912317-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Steven Stein 2026-07-16Form 42026-07-200001673776-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Steven Stein 2026-07-16Form 42026-07-200001673776-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Ramitpal K. Basi 2026-07-16Form 42026-07-200002083591-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Lee Heeson 2026-07-23Form 42026-07-270002039219-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Michael James Morrissey 2026-07-23Form 42026-07-270001780915-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Michael James Morrissey 2026-07-23Form 42026-07-270001780915-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Lee Heeson 2026-07-23Form 42026-07-270002039219-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
134Section 06, 2026 voteForm 8-K2026-06-090000879169-26-000043Item 5.07 · say-on-pay result. As reported: 83.86% (votes for as printed: 145,851,784). Filing ↗
135Section 06, 2025 voteForm 8-K2025-06-110000879169-25-000062Item 5.07 · say-on-pay result. As reported: 92.2% (votes for as printed: 153,838,972). Filing ↗
136Section 06, 2024 voteForm 8-K2024-06-140000879169-24-000082Item 5.07 · say-on-pay result. As reported: 89.59% (votes for as printed: 171,688,040). Filing ↗
137Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
138Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
139Section 09b board cost (computed)ComputedcomputedCash 400,500 + equity 1,738,988 + all other 0 = 2,139,488, summed across the director compensation table rows.machine: formula: Σ = 2,139,488
140Exelixis, Inc., Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
141Incyte Corp (subject), Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte Corp's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
142Biogen Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
143PTC Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410
144BioMarin Pharmaceutical Inc., Section 10b CEO totalDEF 14A2026-04-210001628280-26-026290CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915
145Moderna, Inc., Section 10b CEO totalDEF 14A2026-03-160001308179-26-000081CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898
146Jazz Pharmaceuticals plc, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
147United Therapeutics Corporation, Section 10b CEO totalDEF 14A2026-04-290001082554-26-000009CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
148BeOne Medicines Ltd., Section 10b CEO totalDEF 14A2026-04-280001104659-26-049655CEO total compensation as printed in BeOne Medicines Ltd.'s own proxy. As printed: 17,943,521. Filing ↗machine: t180 · r2 · c22 · span 1909011–1909021
149Natera, Inc., Section 10b CEO totalDEF 14A2026-04-230001104659-26-047770CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
150Alnylam Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-060001628280-26-023923CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701
151Neurocrine Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
152Illumina, Inc., Section 10b CEO totalDEF 14A2026-04-090001193125-26-149669CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536
153Section 10a, Exelixis, Inc. reciprocityDEF 14A0000939767-26-000046Exelixis, Inc. names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
154Section 10a, Neurocrine Biosciences, Inc. reciprocityDEF 14A0000914475-26-000015Neurocrine Biosciences, Inc. names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
155Section 10a, BeOne Medicines Ltd. reciprocityDEF 14A0001104659-26-049655BeOne Medicines Ltd. names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
156Section 10a, Moderna, Inc. reciprocityDEF 14A0001308179-26-000081Moderna, Inc. names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
157Section 10a, Alnylam Pharmaceuticals, Inc. reciprocityDEF 14A0001628280-26-023923Alnylam Pharmaceuticals, Inc. names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
158Section 10a, BioMarin Pharmaceutical Inc. reciprocityDEF 14A0001628280-26-026290BioMarin Pharmaceutical Inc. names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
159Section 10a, Jazz Pharmaceuticals plc reciprocityDEF 14A0001232524-26-000029Jazz Pharmaceuticals plc names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
160Section 10a, Natera, Inc. reciprocityDEF 14A0001104659-26-047770Natera, Inc. names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
161Section 10a, United Therapeutics Corporation reciprocityDEF 14A0001082554-26-000009United Therapeutics Corporation names Incyte Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
162Section 10a, PTC Therapeutics, Inc. reciprocityDEF 14A0001104659-26-045528PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Incyte Corp. Filing ↗